Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
about
SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoRPPARs and the cardiovascular systemIdentification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationIdentification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activityEffects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentAntidiabetic effects of chamomile flowers extract in obese mice through transcriptional stimulation of nutrient sensors of the peroxisome proliferator-activated receptor (PPAR) family.Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis.A Role for the PPARgamma in Cancer Therapy.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013).Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.Amorfrutins: A promising class of natural products that are beneficial to health.Discontinued drugs in 2006: renal, endocrine and metabolic drugs.Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.Analysis of PPAR-α/γ Activity by Combining 2-D QSAR and Molecular Simulation.The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J MiceLemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice.Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells.A novel strategy for designing the selective PPAR agonist by the "sum of activity" model.Learning from tesaglitazar.Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ.Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties.Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective
P2860
Q24324236-65DCDD69-A42A-48CB-9CBB-0E314E9AFA67Q24642728-A66D6509-A1D8-427E-AEE7-E0BC9FF1E2FCQ28485402-C59A2467-1357-4393-AF40-8A62D7D012EAQ28486003-230FDFBC-735F-4014-94EE-AB354995DA22Q34567151-EB1A50D1-53FE-4108-90C9-E17C6D741A30Q35029623-11DF7D84-4097-4625-94EB-024DB6BE76DEQ35050607-F1642DC1-3E7F-4D2C-A4D8-DE23FE0CA0E1Q36516569-25A6B5CC-CCC4-497C-B17F-D1F1440FBF8AQ36691611-011B9B91-E878-40A5-AEB1-7E6D154E58E6Q37012012-6ECC6752-9069-4008-B1C1-BBA0C8D9FA58Q37016305-7664CDDF-4917-4B5A-A699-7D596C6F4B28Q37182798-D7749C20-F08E-4F7E-A097-B52967EB7552Q37311116-14E73624-0823-4627-B04F-58A0F3F52457Q37656896-47477218-DEB3-4C88-9693-AC8B01D9A063Q37725540-92F4872D-33D9-40EE-A415-49E6C01D940DQ37892300-C852C63A-0976-4193-9FF1-4C0B0B2E82E7Q38128537-9E3BF978-B489-412D-B73B-86D4C1F5AFFBQ38201960-4C0160E4-8E08-41F3-9CE2-B67E9EF14EA4Q38217801-56B26DF0-96F5-42FC-9B74-8FA5E28995F0Q38460231-219F6622-00B3-4FFC-8C3A-BC9F0C3AD97CQ39367068-1CCB68C0-2064-43E8-B187-991DC55BB72EQ39535351-4C51DCED-EE87-4751-BC34-56B5EB65B3BAQ42007043-BD7BAEE3-9A46-4AF8-BDFB-64A631EC8BB2Q42239435-FB1AB1C1-9976-4504-8FE2-EB4049BFDA92Q42808299-9564F43F-E501-4626-B7C1-93CCA9486CBCQ42964673-F41257DE-C1C9-4CEF-84F7-B7415A0E5DD1Q46973489-04BFACBD-61C7-453E-A11C-B3A5D3BD068AQ47130302-E4018E0C-6CEE-4907-B27A-7196E888B0DDQ50988033-47D86191-8B06-4933-B64D-E92710696088Q51357963-AD3B29EB-AF05-4462-8437-0BFD47C1F930Q58919671-421B37A2-9689-4F44-9B57-406038D32C5F
P2860
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@ast
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@en
type
label
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@ast
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@en
prefLabel
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@ast
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@en
P2860
P50
P1476
Selective PPAR modulators, dua ...... diabetes and atherosclerosis.
@en
P2093
Corine Glineur
P2860
P304
P356
10.1517/14728214.11.3.379
P407
P577
2006-09-01T00:00:00Z